Korean study tracks Koselugo's Real-World impact on rare nerve tumors

NCT ID NCT06360406

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times

Summary

This study is observing 200 people in South Korea who are already prescribed Koselugo for neurofibromatosis type 1 (NF1) with plexiform neurofibromas. Researchers will track side effects and how well the drug works in everyday medical practice. The goal is to confirm the drug's safety and effectiveness outside of controlled clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Busan, South Korea

  • Research Site

    RECRUITING

    Chungcheongbuk-do, South Korea

  • Research Site

    RECRUITING

    Daejeon, South Korea

  • Research Site

    RECRUITING

    Gyeonggi-do, South Korea

  • Research Site

    RECRUITING

    Incheon, South Korea

  • Research Site

    RECRUITING

    Jeonnam, South Korea

  • Research Site

    SUSPENDED

    Seoul, South Korea

  • Research Site

    RECRUITING

    Seoul, South Korea

  • Research Site

    COMPLETED

    Seoul, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, South Korea

  • Research Site

    RECRUITING

    Wŏnju, South Korea

  • Research Site

    RECRUITING

    Yangsan, South Korea

Conditions

Explore the condition pages connected to this study.